New AI Tool Can Predict Your Type 1 Diabetes Risk More Accurately Than Ever Before
- May 3
- 5 min read
A breakthrough study from UC San Diego has developed a machine learning model that identifies Type 1 diabetes risk in a broader population — including people who would have been missed by older genetic tests.
What Just Changed in Type 1 Diabetes Genetic Screening
For decades, genetic testing for Type 1 diabetes (T1D) has had a significant blind spot: it worked best for people who already carried the most well-known high-risk gene variants. If you didn't have those specific markers, existing tools could miss you entirely — even if diabetes was in your future.
That gap may now be closing. Researchers at the University of California San Diego published a landmark study on April 30, 2026, in the journal Nature Genetics, introducing a machine learning tool called T1GRS (Type 1 Genetic Risk Score). It's designed to predict who will develop Type 1 diabetes with significantly greater accuracy — and across a much wider range of people — than any previous method.
For the Type 1 diabetes community, this is a big deal.
How the T1GRS Tool Works
Type 1 diabetes is an autoimmune disease in which the immune system destroys the insulin-producing beta cells in the pancreas. Because the body can no longer make insulin — the hormone that regulates blood sugar — people with T1D must rely on external insulin for the rest of their lives.
Genetics plays a major role in T1D risk, but the genetic picture is complex. It's not just one or two genes; it's hundreds of variants across the genome interacting with each other in ways that older risk models couldn't fully capture.
The UCSD team addressed this by building T1GRS on a dataset of more than 20,000 people with Type 1 diabetes and nearly 800,000 without it — all of European ancestry. They identified disease-linked variants at 79 known genetic locations, plus 13 new locations not previously linked to T1D that appear to influence immune function, gene regulation, and blood sugar control.
They also performed a deep dive into the major histocompatibility complex (MHC), a region on chromosome 6 that holds the strongest known genetic associations with T1D. Using data from more than 29,000 people, they uncovered several novel variants in the MHC that influence immune function and gene activation.
T1GRS then uses machine learning to analyze non-linear interactions among 199 risk variants spread across the genome and within the MHC, generating each person's overall risk score.
The result? A tool that catches high-risk individuals who would have been invisible to older tests.
"We were able to identify individuals who get diabetes but don't have known high-risk genetic regions at a much higher rate than the previous diagnostic," said co-first author TJ Sears, PhD, a postdoctoral fellow at UC San Diego School of Medicine.
Why This Matters: Earlier Detection, Better Outcomes
The earlier Type 1 diabetes is identified, the better. Early detection allows families and doctors to:
Monitor blood sugar closely before a formal diagnosis
Reduce the risk of diabetic ketoacidosis (DKA) at the time of diagnosis — a dangerous and sometimes life-threatening condition
Identify candidates for preventive therapies, such as teplizumab, an FDA-approved drug that can delay the onset of Stage 3 T1D in high-risk individuals
Co-first author Carolyn McGrail, PhD, emphasized this directly: "Genetic risk scoring allows us to capture a broader pool of both children and adults who are at high risk for T1D but who might otherwise be missed. This supports close monitoring to reduce the risk of complications such as diabetic ketoacidosis at diagnosis and helps identify individuals eligible for preventative therapies like teplizumab."
The Four Sub-Types of Type 1 Diabetes
One of the most intriguing findings of this study is what the researchers discovered when they looked at which genetic features most influenced each person's T1GRS score. They found that people with T1D could be grouped into four distinct genetic sub-types, each with its own disease pattern:
1. MHC-Driven Primarily defined by the well-known high-risk genetic variants associated with T1D. People in this group tend to develop diabetes in childhood — the classic early-onset picture most people associate with T1D.
2. MHC-Enriched Influenced by a blend of variants both inside and outside the MHC region. These individuals tend to develop T1D slightly later than the MHC-driven group, with an intermediate severity pattern.
3. T-Cell-Enriched Driven largely by variants outside the MHC that affect the adaptive immune system — the branch of immunity that includes T-cells, which are known to play a role in the autoimmune attack on the pancreas. Age of onset is also intermediate.
4. Pancreas-Enriched Influenced mainly by non-MHC variants that impact pancreatic cells, including the insulin-producing beta cells. Despite having a later age of onset, this group carries the highest risk of serious complications — including kidney disease, nerve damage, and cardiovascular problems.
This sub-typing could eventually pave the way for more personalized treatment approaches, where care is tailored to a person's specific genetic profile rather than a one-size-fits-all protocol.
Does This Work for Non-European Populations?
One of the common criticisms of genetic research is that it tends to be built on data from people of European ancestry, limiting its applicability to everyone else. The UCSD team took this concern seriously.
When they tested T1GRS on genetic datasets from the NIH All of Us Research Program and the National Pancreatic Organ Donor (nPOD) biobank — which include individuals from diverse backgrounds — the model still predicted T1D risk with 87% accuracy, even though it was built on European ancestry data.
"We were able to do a really good job of predicting risk in non-European populations as well, even though T1GRS was developed in individuals of European descent," said co-first author Emily Griffin, PhD, a postdoctoral fellow at UC San Diego School of Medicine.
Importantly, individuals from these diverse datasets were classified into the same four genetic sub-types — suggesting the sub-typing system is biologically meaningful and not an artifact of the study population.
What This Means for Families Living With Type 1 Diabetes
If you have a child with T1D, or if T1D runs in your family, tools like T1GRS could become an important part of future screening — especially for newborns and young children whose risk might otherwise go undetected until they're already in crisis.
The study reinforces what many T1D families already know: early knowledge is power. Knowing a child is at high genetic risk gives families time to prepare, monitor, and work with their care team to intervene before the disease takes hold.
While T1GRS is not yet a clinical product available at your doctor's office, the research team has noted its strong potential as a widespread clinical screening tool. As this technology moves toward real-world implementation, it represents a meaningful step forward for the T1D community.
The Bottom Line
The UC San Diego T1GRS study represents a significant advance in our ability to predict Type 1 diabetes risk before the disease develops. By combining machine learning with one of the largest genetic datasets ever used for T1D research, scientists have built a tool that:
Identifies more at-risk individuals than previous methods, including those without classic high-risk gene variants
Works across diverse ancestry backgrounds with high accuracy
Uncovers four distinct T1D sub-types that may guide future personalized treatment
Supports earlier detection that could reduce life-threatening complications at diagnosis
As the research moves from the lab toward clinical use, it offers genuine hope — not just for prediction, but for prevention and better care for millions of people living with or at risk for Type 1 diabetes.
Stay informed on the latest diabetes research and management strategies at DirectDiabetes.com.
Sources:
Griffin E, Sears TJ, McGrail C, et al. Nature Genetics, April 30, 2026.
